Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group.
Ueki K, et al.
BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787.
BMJ Open Diabetes Res Care. 2021.
PMID: 33441417
Free PMC article.